Curaleaf Goes Hostile with 45% Premium Bid for Aurora Cannabis
CURLF sits 83% above its 52-week low of $5.4 on light trading volume (0.1× avg).
Summary
Curaleaf announced a hostile takeover bid for Aurora Cannabis, offering US$4.00 per share (45% premium) in stock and cash. The deal would create a global cannabis leader with over US$1.5B in revenue and US$40M in expected synergies.
Updates
· SEC 8-K — Curaleaf formally commenced the offer and filed the take-over bid circular, with the offer open until 5:00 p.m. MT on December 1, 2026, subject to a cap price of US$5.00 per share.
Key Events · M&A and Partnerships · CURLF
-
Hostile Takeover Bid Announced
Curaleaf intends to launch a take-over bid for all Aurora Cannabis shares at US$4.00 per share, comprising 0.3463 Curaleaf shares plus US$0.75 cash.
-
Premium to Aurora Shareholders
The offer represents a 45% premium to Aurora's 30-day VWAP of US$2.75, and a 110% premium excluding Aurora's balance sheet cash.
-
Strategic Rationale
Combines Aurora's EU-GMP cultivation capacity with Curaleaf's distribution platform; expected to generate at least US$40 million in annual cost synergies.
-
Pro Forma Scale
Combined company would have over US$1.5 billion in LTM revenue, nearly US$350 million in LTM Adjusted EBITDA, and a pro forma market cap approaching US$3.0 billion.
Analysis · CURLF · Life Sciences
After private overtures were rebuffed, Curaleaf is taking its bid for Aurora Cannabis directly to shareholders. The offer values Aurora at US$4.00 per share—a 45% premium to its 30-day VWAP—through a mix of Curaleaf stock and cash. This transformative move would create a global cannabis leader with over US$1.5 billion in LTM revenue and nearly US$350 million in LTM Adjusted EBITDA. Because Aurora's board has refused to engage, the unsolicited bid bypasses management. Notably, the deal is not subject to financing or due diligence conditions, signaling Curaleaf's confidence, though execution risk remains given Aurora's resistance and potential defensive tactics.
How filings like this one have moved
In the 30 days to Oct 17, 2026, 44.5% of the 299 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.30%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CURLF was trading at $9.89 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $5.40 to $15.15. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.